Company intelligence / Profile preview
ENSEM Therapeutics
Medford, Massachusetts, United Statesensemtx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ENSEM Therapeutics has developed ETX-197, a CDK2 inhibitor that is close to filing an IND to treat some breast cancers. The company out-licensed global rights for this candidate to BeiGene in November 2023.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
BeiGene
Beyond the preview
Go deeper on ENSEM Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENSEM Therapeutics.